On October 29, 2025 Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), reported it has entered into a collaboration with Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease. The partnership agreement will focus on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to collaborate with Ernexa Therapeutics as they advance a bold and highly differentiated approach to treating cancer," said Darren Head, CEO of Cellipont Bioservices. "Supporting the development of synthetic, allogeneic iMSC therapies like ERNA-101 aligns with our commitment to enabling scientific innovation through collaborative, high-quality cell therapy manufacturing."
"Cellipont brings deep technical capabilities and a shared sense of urgency to help us translate the promise of ERNA-101 into a clinically viable therapy," said Sanjeev Luther, President and CEO of Ernexa Therapeutics. "This collaboration marks an important milestone in advancing our iMSC platform, which we believe has the potential to reshape the treatment landscape for patients with advanced solid tumors."
Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). iMSC is a more specialized type of stem cell that has a unique ability to migrate toward tumors. Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting. ERNA-101 is Ernexa’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells.
In preclinical studies, presented at this year’s AACR (Free AACR Whitepaper) and ASCO (Free ASCO Whitepaper) annual meetings, ERNA-101 has shown the potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth. The Cellipont partnership will support the current Good Manufacturing Practice (cGMP) development and scale-up of the ERNA-101 manufacturing process in preparation for upcoming clinical trials.
(Press release, Ernexa Therapeutics, OCT 29, 2025, View Source [SID1234657121])